Manager: Mark Holder Model: Opportunistic Arbitrage Disclosure: Long PUDA, LIWA, NUVA, RIGL, SVNT, AER, LIZ, X, LLNW as of time of writing This model had a difficult month in April as it underperformed the S&P 500 by a disappointing margin: down 1.6% versus a 2.85% gain for the index. The […]
CEPH
5 posts
Author: Mark Holder Model: Opportunistic Arbitrage Model Disclosure: Long X, WFT, FCX, IBN, CCIH, RDWR, ANR, MEE, CEPH March was another volatile month. The month ended on a solid note with the Opportunistic Arbitrage (levered) model ending with a 2.3% gain compared to a slight loss for the S&P500. Considering […]
Author: Mark Holder Models: Opportunistic Arbitrage Long Only Disclosure: Long RDWR, CCIH, LNC March was another volatile month. The month ended on a solid note with the Opportunistic Arbitrage Long Only model ending with a 1.7% gain compared to a slight loss for the S&P500. Considering this model ended the month […]
Author: Mark Holder Covestor model: Opportunistic Arbitrage Disclosure: Long FCX, IBN, CCIH, RDWR, ATW, SHLD, PUDA, CEPH, MEE, ANR *See important disclosures After a disappointing January, February was a welcome return to outperforming the market. The model returned approximately 3% greater than the S&P500. The market remained strong even in […]
Limiting portfolio sizes to 20-30 stocks allows for diversification without getting to levels of diworstification. Hence, I have always had a few 'risky' biotech stocks. Based on the results of Savient Pharma (SVNT) the rewards have clearly outweighed the risks. Additionally, Rigel Pharma (RIGL) and Cephalon (CEPH) have seen bullish trading of late. Not being predisposed to investing in this sector, I just found the valuations too compelling.